PhaseBio Pharmaceuticals, Inc. ( PHAS) Stock. Should you Buy or Sell? $ 1.10
-0.01 (-1.38 %)
PhaseBio Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | PHAS |
| Price | $1.10 |
| Beta | 2.468 |
| Volume Avg. | $326.54 thousand |
| Market Cap | $54.84 M |
| 52 Week Range | $0.5 - $4.1 |
PhaseBio Pharmaceuticals, Inc. opened the day at $1.10 which is -1.38 % on yesterday's close. PhaseBio Pharmaceuticals, Inc. has a 52 week high of $4.1 and 52 week low of $0.5, which is a difference of $3.6. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $54.84 M and total net profit is $10831 which means the company is trading at 5063.61 times profit to market capitalization. Theoretically, if you were to buy PhaseBio Pharmaceuticals, Inc. for $54.84 M, it would take 15 years to get your money back. PhaseBio Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
PhaseBio Pharmaceuticals, Inc. Stock Forecast - Is PhaseBio Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Buy | |
| ROA Score | Strong Sell | |
| DE Score | Sell | |
| PE Score | Neutral | |
| PB Score | Neutral | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | 1.925 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -2.809 |
Valuing PhaseBio Pharmaceuticals, Inc.
| Price Book Value Ratio | -0.461 | Price To Book Ratio | -0.461 |
| Price To Sales Ratio | -5.409 | Price Earnings Ratio | 1.925 |
How liquid is PhaseBio Pharmaceuticals, Inc.
| Current Ratio | 0.469 |
| Quick Ratio | 0.316 |
Debt
| Debt Ratio | 6.296 | Debt Equity Ratio | -1.189 |
| Long Term Debt To Capitalization | -0.007 | Total Debt To Capitalization | -0.048 |
Latest news about PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -3.03% and 91.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The decision follows COVID-19 impacts on manufacturing, associated drug supply, and enrollment rate in the study.
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor. The trial included patients with urgent surgery or an invasive procedure or experiencing uncontrolled major or life-threatening bleeding.
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -6.45% and -87.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
About PhaseBio Pharmaceuticals, Inc.
Description :
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
